Mesoblast Stock Price, News & Analysis (NASDAQ:MESO)

$5.89 0.25 (4.43 %)
(As of 01/16/2018 04:00 PM ET)
Previous Close$5.64
Today's Range$5.73 - $6.05
52-Week Range$4.80 - $12.50
Volume91,000 shs
Average Volume42,122 shs
Market Capitalization$529.47 million
P/E Ratio-7.18
Dividend YieldN/A
Beta2.44

About Mesoblast (NASDAQ:MESO)

Mesoblast logoMesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

Receive MESO News and Ratings via Email

Sign-up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:MESO
CUSIPN/A
Phone+61-3-96396036

Debt

Debt-to-Equity RatioN/A
Current Ratio3.53%
Quick Ratio3.53%

Price-To-Earnings

Trailing P/E Ratio-7.18292682926829
Forward P/E Ratio-6.47
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.41 million
Price / Sales209.30
Cash FlowN/A
Price / CashN/A
Book Value$6.03 per share
Price / Book0.98

Profitability

Trailing EPS($0.82)
Net Income$-76,810,000.00
Net Margins-2,006.86%
Return on Equity-12.04%
Return on Assets-9.60%

Miscellaneous

Employees108
Outstanding Shares85,640,000

Mesoblast (NASDAQ:MESO) Frequently Asked Questions

What is Mesoblast's stock symbol?

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

How were Mesoblast's earnings last quarter?

Mesoblast Limited (NASDAQ:MESO) announced its earnings results on Tuesday, November, 14th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.15. Mesoblast had a negative net margin of 2,006.86% and a negative return on equity of 12.04%. View Mesoblast's Earnings History.

When will Mesoblast make its next earnings announcement?

Mesoblast is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for Mesoblast.

Where is Mesoblast's stock going? Where will Mesoblast's stock price be in 2018?

6 equities research analysts have issued 12 month price targets for Mesoblast's shares. Their predictions range from $8.50 to $20.00. On average, they expect Mesoblast's share price to reach $14.25 in the next year. View Analyst Ratings for Mesoblast.

What are Wall Street analysts saying about Mesoblast stock?

Here are some recent quotes from research analysts about Mesoblast stock:

  • 1. Cantor Fitzgerald analysts commented, "Heart Failure Holds Focus. In C1Q18, we expect top-line results of the Phase 2b, 159-patient, end-stage heart failure and LVAD study. We anticipate that disclosure of the top-line data on patient functional status (LVAD weaning) will remain limited until overall survival results (up to 12 months) become available. A successful outcome could accelerate the regulatory path of the overall cardiac program, in our view, especially considering recently awarded RMAT designation for the LVAD program." (1/16/2018)
  • 2. According to Zacks Investment Research, "Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. " (1/13/2018)
  • 3. Maxim Group analysts commented, "Mesoblast announced that TiGenix paid to license IP. We view this early decision by Belgium-based TiGenix (TIG – NR) as an indication of the strength of Mesoblast’s IP estate. As a result, Mesoblast gives TiGenix freedom to operate (global commercialization) for the company’s adipose stem cell product Cx601," for the local treatment of fistulae. Mesoblast will receive up to €20 million (approximately USD$24 million) in payments, with €5 million upfront, €5 million within 12 months, and up to €10 million in product regulatory milestones. Additionally, Mesoblast will receive single digit royalties on net sales of Cx601." (12/18/2017)

Who are some of Mesoblast's key competitors?

Who are Mesoblast's key executives?

Mesoblast's management team includes the folowing people:

  • Silviu Itescu, Chief Executive Officer, Executive Director
  • William A. Burns, Vice Chairman of the Board
  • Paul Hodgkinson, Group Chief Financial Officer
  • Peter Howard, General Counsel, Corporate Executive
  • John McMannis Ph.D., Head of Manufacturing
  • Paul Simmons Ph.D., Head of Research and New Product Development
  • Donna Skerrett M.D., Chief Medical Officer
  • Geraldine Storton MBA, Head of Regulatory Affairs and Quality Management
  • Charlie Harrison, Company Secretary
  • Brian Jamieson, Independent Non-Executive Chairman of the Board

When did Mesoblast IPO?

(MESO) raised $69 million in an initial public offering on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

How do I buy Mesoblast stock?

Shares of Mesoblast can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mesoblast's stock price today?

One share of Mesoblast stock can currently be purchased for approximately $5.83.

How big of a company is Mesoblast?

Mesoblast has a market capitalization of $529.47 million and generates $2.41 million in revenue each year. The company earns $-76,810,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. Mesoblast employs 108 workers across the globe.

How can I contact Mesoblast?

Mesoblast's mailing address is L 38 55 Collins St, MELBOURNE, VIC 3000, Australia. The company can be reached via phone at +61-3-96396036 or via email at [email protected]


MarketBeat Community Rating for Mesoblast (MESO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  225
MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mesoblast (NASDAQ:MESO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.50
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.25$14.25$14.25$13.38
Price Target Upside: 141.94% upside163.89% upside155.83% upside74.38% upside

Mesoblast (NASDAQ:MESO) Consensus Price Target History

Price Target History for Mesoblast (NASDAQ:MESO)

Mesoblast (NASDAQ:MESO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018Cantor FitzgeraldSet Price TargetBuy$20.00LowView Rating Details
12/20/2017OppenheimerSet Price TargetBuy$16.00LowView Rating Details
12/18/2017Maxim GroupSet Price TargetBuy$14.00HighView Rating Details
8/31/2017CIBCInitiated CoverageOutperform -> Outperform$16.00HighView Rating Details
7/18/2017Credit Suisse GroupSet Price TargetHold$11.00LowView Rating Details
4/3/2017ScotiabankReiterated RatingHold$8.50LowView Rating Details
6/15/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
2/25/2016Chardan CapitalReiterated RatingHoldN/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Mesoblast (NASDAQ:MESO) Earnings History and Estimates Chart

Earnings by Quarter for Mesoblast (NASDAQ:MESO)

Mesoblast (NASDAQ MESO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018        
11/14/2017Q1 2018($0.23)($0.08)ViewN/AView Earnings Details
8/29/2017Q4 2017($0.32)ViewN/AView Earnings Details
5/24/2017Q3 2017($0.12)ViewN/AView Earnings Details
2/26/2017Q2 2017($0.26)ViewN/AView Earnings Details
11/14/2016Q1 2017($0.26)ViewN/AView Earnings Details
8/25/2016Q4 2016$1.17ViewN/AView Earnings Details
5/9/2016Q3 2016($0.22)ViewN/AView Earnings Details
2/16/2016Q2 2016($0.31)ViewN/AView Earnings Details
12/17/2015Q1 2016($0.20)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Mesoblast (NASDAQ:MESO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.57)
2019 EPS Consensus Estimate: ($0.54)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181($0.19)($0.19)($0.19)
Q3 20181($0.19)($0.19)($0.19)
Q4 20181($0.19)($0.19)($0.19)
Q1 20191($0.19)($0.19)($0.19)
Q2 20191($0.20)($0.20)($0.20)
Q3 20191($0.21)($0.21)($0.21)
Q4 20191$0.06$0.06$0.06
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Mesoblast (NASDAQ:MESO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Mesoblast (NASDAQ MESO)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Mesoblast (NASDAQ MESO) News Headlines

Source:
DateHeadline
Mesoblast (MESO) Raised to Buy at Zacks Investment ResearchMesoblast (MESO) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - January 13 at 10:54 AM
Mesoblast Limited (MESO) Receives Consensus Rating of "Hold" from BrokeragesMesoblast Limited (MESO) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 10 at 5:38 AM
ETFs with exposure to Mesoblast Ltd. : December 28, 2017ETFs with exposure to Mesoblast Ltd. : December 28, 2017
finance.yahoo.com - December 28 at 3:50 PM
Mesoblast Ltd. :MESO-US: Earnings Analysis: Q1, 2018 By the Numbers : December 27, 2017Mesoblast Ltd. :MESO-US: Earnings Analysis: Q1, 2018 By the Numbers : December 27, 2017
finance.yahoo.com - December 28 at 9:03 AM
Mesoblast receives RMAT designation from FDA for its cell therapy in heart failure patients with LVADs - Seeking AlphaMesoblast receives RMAT designation from FDA for its cell therapy in heart failure patients with LVADs - Seeking Alpha
seekingalpha.com - December 22 at 9:04 PM
Oppenheimer Weighs in on Mesoblast Limiteds FY2020 Earnings (MESO)Oppenheimer Weighs in on Mesoblast Limited's FY2020 Earnings (MESO)
www.americanbankingnews.com - December 21 at 10:56 PM
Mesoblasts Phase 3 Trial in Children With Acute Graft Versus Host ... - NasdaqMesoblast's Phase 3 Trial in Children With Acute Graft Versus Host ... - Nasdaq
www.nasdaq.com - December 20 at 5:10 PM
Mesoblast (MESO) PT Set at $16.00 by OppenheimerMesoblast (MESO) PT Set at $16.00 by Oppenheimer
www.americanbankingnews.com - December 20 at 2:16 PM
Stem Cells as Medicine: The Promise of Universal Donor Adult Stem Cells Continues to Attract OptimismStem Cells as Medicine: The Promise of Universal Donor Adult Stem Cells Continues to Attract Optimism
finance.yahoo.com - December 20 at 9:41 AM
Financial Comparison: Mesoblast (MESO) and Its PeersFinancial Comparison: Mesoblast (MESO) and Its Peers
www.americanbankingnews.com - December 19 at 8:18 AM
Wired News – TiGenix Received an Exclusive Global Patent License to Cx601 from Mesoblast in the Local Treatment of FistulaeWired News – TiGenix Received an Exclusive Global Patent License to Cx601 from Mesoblast in the Local Treatment of Fistulae
finance.yahoo.com - December 18 at 9:58 AM
Maxim Group Analysts Give Mesoblast (MESO) a $14.00 Price TargetMaxim Group Analysts Give Mesoblast (MESO) a $14.00 Price Target
www.americanbankingnews.com - December 18 at 8:57 AM
Mesoblast Limited (MESO) Receives Average Recommendation of "Hold" from AnalystsMesoblast Limited (MESO) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 16 at 5:42 AM
Ionis Pharmaceuticals (IONS) & Mesoblast (MESO) Head to Head ReviewIonis Pharmaceuticals (IONS) & Mesoblast (MESO) Head to Head Review
www.americanbankingnews.com - December 15 at 11:16 PM
Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the ... - GlobeNewswire (press release)Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the ... - GlobeNewswire (press release)
globenewswire.com - December 15 at 10:03 AM
Mesoblast (MESO) versus Its Rivals Head-To-Head AnalysisMesoblast (MESO) versus Its Rivals Head-To-Head Analysis
www.americanbankingnews.com - December 13 at 1:30 AM
Mesoblast Named Global Technology Leader in Cell Therapy Industry - Business Wire (press release)Mesoblast Named Global Technology Leader in Cell Therapy Industry - Business Wire (press release)
www.businesswire.com - December 12 at 10:05 AM
Mesoblast (MESO) and GenVec (GNVC) Head-To-Head AnalysisMesoblast (MESO) and GenVec (GNVC) Head-To-Head Analysis
www.americanbankingnews.com - December 12 at 3:24 AM
Contrasting Portola Pharmaceuticals (PTLA) & Mesoblast (MESO)Contrasting Portola Pharmaceuticals (PTLA) & Mesoblast (MESO)
www.americanbankingnews.com - December 10 at 3:26 AM
Mesoblast Named Global Technology Leader in Cell Therapy Industry - GlobeNewswire (press release)Mesoblast Named Global Technology Leader in Cell Therapy Industry - GlobeNewswire (press release)
www.globenewswire.com - December 7 at 5:36 PM
Mesoblast Named Global Technology Leader in Cell Therapy IndustryMesoblast Named Global Technology Leader in Cell Therapy Industry
finance.yahoo.com - December 7 at 5:36 PM
Mesoblast Limited (MESO) to Post FY2018 Earnings of ($0.80) Per Share, Cantor Fitzgerald ForecastsMesoblast Limited (MESO) to Post FY2018 Earnings of ($0.80) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - November 22 at 1:58 PM
Financial Review: Mesoblast Limited (MESO) vs. Its PeersFinancial Review: Mesoblast Limited (MESO) vs. Its Peers
www.americanbankingnews.com - November 21 at 2:12 PM
Mesoblast Limited (MESO) Given Consensus Recommendation of "Hold" by AnalystsMesoblast Limited (MESO) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 21 at 8:24 AM
Mesoblast Limited (MESO) Given a $16.00 Price Target by Oppenheimer Holdings, Inc. AnalystsMesoblast Limited (MESO) Given a $16.00 Price Target by Oppenheimer Holdings, Inc. Analysts
www.americanbankingnews.com - November 19 at 10:20 PM
Maxim Group Analysts Give Mesoblast Limited (MESO) a $14.00 Price TargetMaxim Group Analysts Give Mesoblast Limited (MESO) a $14.00 Price Target
www.americanbankingnews.com - November 19 at 5:38 PM
Zacks Investment Research Lowers Mesoblast Limited (MESO) to Strong SellZacks Investment Research Lowers Mesoblast Limited (MESO) to Strong Sell
www.americanbankingnews.com - November 18 at 10:52 PM
Mesoblast Limited Forecasted to Earn Q2 2018 Earnings of ($0.19) Per Share (MESO)Mesoblast Limited Forecasted to Earn Q2 2018 Earnings of ($0.19) Per Share (MESO)
www.americanbankingnews.com - November 17 at 11:52 PM
Chairman’s Address to the Mesoblast 2017 Annual General MeetingChairman’s Address to the Mesoblast 2017 Annual General Meeting
finance.yahoo.com - November 17 at 3:59 PM
Mesoblast Operational Highlights and Financial Results for the First Quarter Ended September 30, 2017 - GlobeNewswire (press release)Mesoblast Operational Highlights and Financial Results for the First Quarter Ended September 30, 2017 - GlobeNewswire (press release)
globenewswire.com - November 15 at 6:20 AM
Mesoblast to Host First Quarter Financial Results Webcast and Conference Call - GlobeNewswire (press release)Mesoblast to Host First Quarter Financial Results Webcast and Conference Call - GlobeNewswire (press release)
globenewswire.com - November 15 at 6:20 AM
Why Mesoblast limited remains a capital sinkhole - Motley Fool AustraliaWhy Mesoblast limited remains a capital sinkhole - Motley Fool Australia
www.fool.com.au - November 15 at 6:20 AM
Reviewing Mesoblast Limited (MESO) & Protagonist Therapeutics (PTGX)Reviewing Mesoblast Limited (MESO) & Protagonist Therapeutics (PTGX)
www.americanbankingnews.com - November 14 at 1:36 PM
Mesoblast to Host First Quarter Financial Results Webcast and Conference CallMesoblast to Host First Quarter Financial Results Webcast and Conference Call
feeds.benzinga.com - November 13 at 5:49 PM
Mesabi Trust (MESO) Phase 2 RA Trial Shows Early and Durable EffectsMesabi Trust (MESO) Phase 2 RA Trial Shows Early and Durable Effects
www.streetinsider.com - November 12 at 6:21 AM
Mesoblasts MPC therapy shows durable effect in mid-stage RA study; shares ahead 2%Mesoblast's MPC therapy shows durable effect in mid-stage RA study; shares ahead 2%
seekingalpha.com - November 12 at 6:21 AM
BRIEF-MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTSBRIEF-MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTS
www.reuters.com - November 12 at 6:21 AM
ETFs with exposure to Mesoblast Ltd. : November 6, 2017ETFs with exposure to Mesoblast Ltd. : November 6, 2017
finance.yahoo.com - November 7 at 6:44 AM
Mesoblast Limited (MESO) Receives Average Recommendation of "Hold" from BrokeragesMesoblast Limited (MESO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 27 at 7:58 AM
Here’s why the Mesoblast limited share price is getting slammed todayHere’s why the Mesoblast limited share price is getting slammed today
www.fool.com.au - October 25 at 7:12 AM
ETFs with exposure to Mesoblast Ltd. : October 23, 2017ETFs with exposure to Mesoblast Ltd. : October 23, 2017
finance.yahoo.com - October 24 at 5:30 AM
Critical Analysis: Chromadex Corp (CDXC) vs. Mesoblast Limited (MESO)Critical Analysis: Chromadex Corp (CDXC) vs. Mesoblast Limited (MESO)
www.americanbankingnews.com - October 19 at 8:28 PM
Head to Head Analysis: Mesoblast Limited (MESO) versus Fibrocell Science (FCSC)Head to Head Analysis: Mesoblast Limited (MESO) versus Fibrocell Science (FCSC)
www.americanbankingnews.com - October 16 at 10:30 AM
ETFs with exposure to Mesoblast Ltd. : October 9, 2017ETFs with exposure to Mesoblast Ltd. : October 9, 2017
finance.yahoo.com - October 9 at 4:06 PM
Mesoblast Ltd. :MESO-US: Earnings Analysis: Q4, 2017 By the Numbers : October 6, 2017Mesoblast Ltd. :MESO-US: Earnings Analysis: Q4, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 10:25 AM
Mesoblast Limited (MESO) Upgraded to "Buy" by Zacks Investment ResearchMesoblast Limited (MESO) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - October 5 at 12:26 AM
Global Cell Therapy Market Report 2017-2021: Proliferation of Strategic Alliances and Royalty PaymentsGlobal Cell Therapy Market Report 2017-2021: Proliferation of Strategic Alliances and Royalty Payments
www.finanznachrichten.de - October 4 at 7:33 AM
Mesoblast Limited (MESO) Receives Consensus Rating of "Hold" from AnalystsMesoblast Limited (MESO) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - October 2 at 4:32 AM
Mesoblast Limiteds (MESO) "Buy" Rating Reaffirmed at Maxim GroupMesoblast Limited's (MESO) "Buy" Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - October 1 at 7:40 PM
Research Analysts Offer Predictions for Mesoblast Limiteds Q1 2019 Earnings (MESO)Research Analysts Offer Predictions for Mesoblast Limited's Q1 2019 Earnings (MESO)
www.americanbankingnews.com - September 29 at 1:52 PM

SEC Filings

Mesoblast (NASDAQ:MESO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Mesoblast (NASDAQ MESO) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.